Tiny tablets could make PKU management easier for patients
NCT ID NCT07671859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new microtablet protein substitute for people with phenylketonuria (PKU), a condition requiring a strict low-protein diet. The microtablets combine protein with vitamins and minerals, aiming to be easier to take than current liquid or powder options. About 20 adults and children (ages 4+) will try the tablets for 28 days, and researchers will check how well they tolerate and accept them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amino acid based microtablet protein substitute with vitamins and minerals
What this could lead to
If successful, this could offer a more convenient and acceptable way for people with PKU to manage their condition, potentially improving daily compliance.
What could go wrong
This is a very small, early case series (20 people) lasting only 29 days, so results may not apply to everyone. It focuses on tolerance and acceptability, not long-term health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA (PKU) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, United Kingdom